Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions

Table 7

Pharmacokinetic parameters of tolbutamide in the treated group and control group.

Pharmacokinetic parameters	Treated group	Control group
t1/2 (h)	5.33 ± 3.51	2.46 ± 0.11
Tmax (h)	6.67 ± 3.01	6.00 ± 2.00
Cmax (mg/L)	60.70 ± 10.70	82.72 ± 4.84
AUC0-t	866.95 ± 147.51	923.84 ± 122.76
AUC0-∞	867.29 ± 147.80	923.84 ± 122.76
Vd (L/kg)	0.27 ± 0.15	0.12 ± 0.01
CL (L/h/kg)	0.04 ± 0.01	0.03 ± 0.00

Pharmacokinetic parameters were calculated by DAS 3.2.8 software. t1/2: elimination half-life; T_max: the time of peak concentration; C_max: the maximum concentration; AUC0-t, AUC0-∞: area under the plasma concentration-time profiles; V_d: volume of distribution; CL: clearance. compared with the control group.